Parathyroid hormone in osteoporosis

被引:2
作者
Cormier, C [1 ]
机构
[1] Hop Cochin, Serv Rhumatol A, APHP, F-75014 Paris, France
来源
PRESSE MEDICALE | 2006年 / 35卷 / 03期
关键词
D O I
10.1016/S0755-4982(06)74624-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Continuous parathyroid hormone secretion caused by primary hyperparathyroidism contributes to osteoporosis. Laboratory tests, in particular the intact PTH assay make the diagnosis of hyperparathyroidism, certain. In hyperparathyroidism, the bone damage primarily affects the cortical bone, especially the proximal one-third of the radius and to a lesser degree the upper femur, the lumbar spine is affected more rarely. Intermittent administration of parathyroid hormone stimulates bone formation and is useful in treating osteoporosis. Subcutaneous injections once daily administration of PTH stimulates bone formation on the surface of trabecular and cortical bone by preferential stimulation of osteoblastic more than osteoclastic activity.
引用
收藏
页码:495 / 501
页数:7
相关论文
共 39 条
[21]   RISK OF AGE-RELATED FRACTURES IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM [J].
MELTON, LJ ;
ATKINSON, EJ ;
OFALLON, WM ;
HEATH, H .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (11) :2269-2273
[22]   Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. [J].
Neer, RM ;
Arnaud, CD ;
Zanchetta, JR ;
Prince, R ;
Gaich, GA ;
Reginster, JY ;
Hodsman, AB ;
Eriksen, EF ;
Ish-Shalom, S ;
Genant, HK ;
Wang, OH ;
Mitlak, BH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (19) :1434-1441
[23]   Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism -: Four-year follow-up and comparison with healthy postmenopausal women [J].
Orr-Walker, BJ ;
Evans, MC ;
Clearwater, JM ;
Horne, A ;
Grey, AB ;
Reid, IR .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (14) :2161-2166
[24]   Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism [J].
Peacock, M ;
Bilezikian, JP ;
Klassen, PS ;
Guo, MD ;
Turner, SA ;
Shoback, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) :135-141
[25]  
Rao DS, 2002, J BONE MINER RES, V17, pN75
[26]   ANABOLIC EFFECT OF HUMAN PARATHYROID-HORMONE FRAGMENT ON TRABECULAR BONE IN INVOLUTIONAL OSTEOPOROSIS - A MULTICENTER TRIAL [J].
REEVE, J ;
MEUNIER, PJ ;
PARSONS, JA ;
BERNAT, M ;
BIJVOET, OLM ;
COURPRON, P ;
EDOUARD, C ;
KLENERMAN, L ;
NEER, RM ;
RENIER, JC ;
SLOVIK, D ;
VISMANS, FJFE ;
POTTS, JT .
BMJ-BRITISH MEDICAL JOURNAL, 1980, 280 (6228) :1340-1344
[27]   Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate [J].
Rittmaster, RS ;
Bolognese, M ;
Ettinger, MP ;
Hanley, DA ;
Hodsman, AB ;
Kendler, DL ;
Rosen, CJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (06) :2129-2134
[28]   The anabolic effects of parathyroid hormone [J].
Rubin, MR ;
Cosman, F ;
Lindsay, R ;
Bilezikian, JP .
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (04) :267-277
[29]   Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism [J].
Rubin, MR ;
Lee, KH ;
McMahon, DJ ;
Silverberg, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03) :1174-1178
[30]   LONGITUDINAL MEASUREMENTS OF BONE-DENSITY AND BIOCHEMICAL INDEXES IN UNTREATED PRIMARY HYPERPARATHYROIDISM [J].
SILVERBERG, SJ ;
GARTENBERG, F ;
JACOBS, TP ;
SHANE, E ;
SIRIS, E ;
STARON, RB ;
BILEZIKIAN, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :723-728